Worldwide about 240 million people are chronically infected with the hepatitis B virus
(HBV), which is the most common cause for hepatocellular carcinoma. Currently available
treatments for chronic hepatitis B (CHB) suppress viral replication but rarely lead
to eradication of the virus, because an episomal form of the virus, which is called
covalently closed circular DNA (cccDNA), persists in the nucleus of infected cells.
T cell therapy of CHB intends to restore the antiviral T cell immunity, which is necessary
to clear the infection. In the present study, we aimed at identifying T cell receptors
(TCR) with a high functional avidity that can be used for re-direction of T cells.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
